dimethyl fumarate / Generic mfg. - LARVOL DELTA

Proteomic Cysteine Profiling Links DMI and DMF to Antiviral Activity. (PubMed, Proteomics) - "Our findings nominate RIG-I as a shared candidate target of DMI and DMF and associate altered cysteine reactivity with the dampening of antiviral and inflammatory signaling. This work provides new mechanistic insights into the immunosuppressive actions of these electrophiles and highlights their potential as chemical probes and therapeutic leads for modulating innate immunity."

Journal • DDX58

Gut Microbiota-Targeted Therapies in Multiple Sclerosis: A Systematic Review of Clinical Evidence (ACG 2026) - "The included studies demonstrated consistent gut microbiome dysbiosis in MS, characterized by reduced alpha diversity and depletion of short chain fatty acids (SCFA)-producing and anti-inflammatory taxa, including Faecalibacterium, Bifidobacterium , and Roseburia . Increased abundance of pro-inflammatory genera such as Akkermansia, Bacteroides , and Clostridia was also observed. These microbial alterations were associated with elevated inflammatory markers, including IL-6, IL-17, TNF-α, and C-reactive protein, alongside reduced SCFA levels."

Clinical • Gut Microbiota • Review • CNS Disorders • Immunology • Multiple Sclerosis • CRP • IL17A • IL6

Engineering human myelin microphysiological systems for testing patient treatment response in multiple sclerosis. (PubMed, bioRxiv) - "Integration of imaging and flow-cytometric features distinguished healthy-donor, untreated-MS, responder, and nonresponder profiles following treatment with prednisone, glatiramer acetate, interferon β-1a, or dimethyl fumarate. Thus, the myelin MPS platform provides a scalable, human pathophysiology-relevant platform for functional phenotyping and individualized treatment-response evaluation in MS."

Journal • CNS Disorders • Immunology • Inflammation • Multiple Sclerosis • Solid Tumor • IFNB1

TREAT-MS: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (clinicaltrials.gov) - P=N/A | N=900 | Completed | Sponsor: Johns Hopkins University | Active, not recruiting ➔ Completed

Trial completion • CNS Disorders • Multiple Sclerosis

Itaconation and Succination as Metabolite-Derived Cysteine Modifications in Inflammatory Signalling: Biochemical Mechanisms, Chemoproteomic Mapping, and Therapeutic Opportunities. (PubMed, Cell Biochem Biophys) - "Proteomic and chemoproteomic approaches can prioritise metabolite-responsive cysteines, but functional relevance requires site-level validation, residue perturbation, and biochemical rescue. By comparing itaconation and succination across chemistry, target selection, inflammatory signalling, and therapeutic translation, this review defines the evidence needed to identify metabolite-sensitive cysteines as genuine regulatory nodes rather than detectable covalent adducts."

Journal • Review • Metabolic Disorders • KEAP1

Dimethyl Fumarate Enhances Venetoclax-Induced Cell Death by Inhibiting Mitochondrial Respiration and Cell Cycle Control in Colorectal Cancer. (PubMed, Life (Basel)) - "These findings highlight a combined effect targeting redox balance and apoptosis in CRC. Given their clinical availability, DMF and ABT-199 represent a promising combination for further preclinical evaluation."

Journal • Colorectal Cancer • Hematological Disorders • Hematological Malignancies • Oncology • Solid Tumor

IDENTIFYING MEANINGFUL PATIENT SAVINGS ON GENERICS: DIRECT-TO-CONSUMER PRICES VS COMMERCIAL INSURANCE (ISPOR 2026) - "DTC pharmacies such as MCCPDC meaningfully lower out-of-pocket costs for higher-cost generic prescriptions which could otherwise be difficult to afford. Commercially insured patients should consider DTC pharmacies when their copayment or coinsurance for a generic medication exceeds $15, and particularly when it exceeds $100."

Clinical • Reimbursement • US reimbursement • CNS Disorders • Depression • Endocrine Disorders • Erectile Dysfunction • Multiple Sclerosis

Effect of Dimethyl Fumarate on giant cell formation (EADV 2026) - No abstract available

Biomimetic Nano-delivery System with Mesenchymal Stem Cell Membrane-Camouflaged Dimethyl Fumarate Improves COPD-Atherosclerosis Comorbidity (ERS 2026) - "This RAGE-targeted biomimetic nanoplatform enables precise DMF delivery to comorbid lesions. By orchestrating AGEs-RAGE inhibition and Nrf2 activation, it synergistically remodels the microenvironment, offering a dual-targeted strategy for integrated COPD-AS management."

Atherosclerosis • Cardiovascular • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

A novel therapeutic regimen based on the constrained-disorder principles may improve the response to dimethyl fumarate in multiple sclerosis: Findings from an exploratory feasibility open-label clinical trial. (PubMed, IBRO Neurosci Rep) - P=N/A | "Controlled studies are needed to confirm these findings. (NCT06385197)."

Journal • CNS Disorders • Multiple Sclerosis • NEFL

β-Amyloid and Glutathione Dysregulation Cooperatively Drive Lipid Peroxidation and Ferroptosis in Neuron-Like Cells. (PubMed, Free Radic Biol Med) - "Cell death was prevented by ferrostatin-1, liproxstatin-1, and the iron chelator deferoxamine, but not by the pan-caspase inhibitor Z-VAD-FMK, confirming an iron-dependent ferroptotic mechanism...Pharmacological inhibition of lysosomal function with bafilomycin A1 or treatment with the CMA inhibitor polyphyllin D rescued cell viability under these conditions. Collectively, these findings suggest a potential association among CMA activation, reduced GPX4 abundance, and increased susceptibility to ferroptotic cell death, providing new insight into how age-related redox imbalance may contribute to neuronal vulnerability in AD."

Journal • Alzheimer's Disease • CNS Disorders • GPX4

Dimethyl fumarate ameliorates amyloid-beta generated cognitive deficits by inhibiting RIPK1/RIPK3/MLKL necroptosis signalling in rats. (PubMed, Int Immunopharmacol) - "Our results indicate the cognitive improvement and neuroprotective effects of DMF in Aβ1-42 CE model by modulating the necroptosis signalling. We suggest that the selective targeting of necroptosis process may open new treatment avenues for AD."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Multiple Sclerosis • CAT • DLG4 • IL6 • MLKL • RIPK1 • SYP • TNFA

Predictors of high- versus low-intensity first-line multiple sclerosis treatments. (PubMed, Mult Scler J Exp Transl Clin) - "The first DMT filled was classified as either high- (natalizumab, alemtuzumab, ocrelizumab, rituximab, ofatumumab, cladribine) or low-intensity (interferon, glatiramer acetate, teriflunomide, dimethyl fumarate, diroximel fumarate, fingolimod, ponesimod, siponimod, ozanimod)...The minority of MS patients initiated high-intensity treatment although this proportion increased over time, and later years were predictive of high-intensity treatment. Providers had a significant role in the approach selected."

Journal • CNS Disorders • Multiple Sclerosis

Disease-modifying therapy uptake in a pediatric-onset multiple sclerosis population, British Columbia, Canada. (PubMed, J Neuroimmunol) - "Moderate-efficacy therapies were the more common initial DMT dispensed for individuals with POMS, but more than two-thirds eventually received a high-efficacy therapy. Only a minority of POMS cases were first dispensed a DMT under age 18 years."

Journal • CNS Disorders • Multiple Sclerosis • Pediatrics

Dimethyl Fumarate-Associated Acute Hepatocellular Injury Assessed for Causality Using the Updated RUCAM: A Biopsy-Supported Case Report. (PubMed, Clin Case Rep) - "Updated RUCAM assessment yielded 6, indicating probable causality, supported by dechallenge. Negative ANA reduced autoimmune hepatitis likelihood, although untested hepatitis E limited alternative-cause assessment and causal certainty."

Journal • Autoimmune Hepatitis • CNS Disorders • Hepatology • Immunology • Inflammation • Liver Failure • Multiple Sclerosis

Severe invasive pneumococcal pneumonia following influenza A in a patient with multiple sclerosis treated with dimethyl fumarate: the importance of vaccination assessment and hematologic monitoring. (PubMed, J Neurol) - No abstract available

Journal • CNS Disorders • Hematological Disorders • Infectious Disease • Influenza • Multiple Sclerosis • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Oxidative Stress and NRF2-Mediated Redox Regulation in Incomplete Systemic Lupus Erythematosus and Systemic Lupus Erythematosus. (PubMed, Antioxidants (Basel)) - "A similar trend, although not significant, is seen in iSLE patients, which indicates that redox imbalances are already present in early phases, but not as obvious as in established SLE. NRF2 activators upregulate antioxidant gene expression in PBMCs and HaCaT cells, highlighting their potential role to modulate oxidative stress pathways in SLE."

Journal • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus • CAT • HMOX1 • KEAP1 • NQO1 • TXN

Restoring autophagy-apoptosis balance in diabetic cardiomyopathy via a biomimetic, ROS-responsive nanocarrier associated with Mst1 pathway modulation. (PubMed, J Nanobiotechnology) - "Hematological, biochemical, behavioral, and histological safety assessments indicated that NP-APT did not produce evident additional systemic toxicity under the tested treatment conditions in DCM mice. Collectively, this study demonstrates that APT-mediated biomimetic nanodelivery provides an effective strategy to enhance DMF myocardial delivery and ameliorate DCM in association with Mst1-autophagy-apoptosis pathway regulation."

Journal • Cardiomyopathy • Cardiovascular • Diabetes • Fibrosis • Hematological Disorders • Immunology • MST1

Photoassisted chemical vapor deposition of ruthenium on functionalized self-assembled monolayers using (η2-olefin)Ru(CO)4 precursors | Poster Board #1510 (ACS-Fall 2026) - "Notably, Ru deposition occurs even without UV irradiation, indicating that these complexes can also function as room temperature thermal CVD precursors. The characterization results and the influence of stereochemistry on photoassisted chemical deposition will be discussed."

Comparative multi-analyte serum protein differences between generic and brand-name dimethyl fumarate, fingolimod, and teriflunomide in multiple sclerosis. (PubMed, Clin Immunol) - "We compared biomarker variability in MS individuals (n = 1124) treated with generic or brand-name fumarates (diroximel fumarate, dimethyl fumarate (DMF)), fingolimod, and teriflunomide...Additionally, all generic DMTs demonstrated higher multi-variable variability index values across 18 proteins associated with MS disease activity. Greater biomarker variability with generic formulations may reflect differences in therapeutic exposure and less consistent disease control."

Journal • CNS Disorders • Multiple Sclerosis • CCL20 • CXCL13 • CXCL9 • TNFSF13B

FDA-approved Dimethyl Fumarate Targets Thioredoxin Reductase to Induce Apoptosis in Triple-Negative Breast Cancer. (PubMed, Free Radic Biol Med) - "Interestingly, DMF treatment inhibited tumor growth in vivo. Collectively, these findings identify DMF as a novel TrxR inhibitor that induces redox imbalance and apoptosis in TNBC, highlighting its potential as a repurposed therapeutic agent for this aggressive breast cancer subtype."

FDA event • Journal • Breast Cancer • CNS Disorders • Dermatology • Immunology • Multiple Sclerosis • Oncology • Psoriasis • Solid Tumor • Triple Negative Breast Cancer

A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD.

New P2 trial • CNS Disorders • Multiple Sclerosis

Dimethyl Fumarate Treatment for Intracranial Unruptured Aneurysms. (clinicaltrials.gov) - P4 | N=60 | Completed | Sponsor: Beijing Tiantan Hospital | Not yet recruiting ➔ Completed | Trial completion date: Jun 2024 ➔ Jul 2026 | Trial primary completion date: Dec 2023 ➔ Dec 2025

Trial completion • Trial completion date • Trial primary completion date • Cardiovascular • Inflammation • Vascular Neurology

GSDMD-mediated pyroptosis in the dorsal hippocampus is implicated in morphine-induced reward memory in mice. (PubMed, Neuropharmacology) - "Complementary in vitro experiments in HT-22 hippocampal neuronal cells confirmed that morphine directly induces dose-dependent upregulation of pyroptosis-related genes and proteins, effects that were abrogated by DMF co-treatment. These findings identify neuronal pyroptosis as a previously unrecognized mechanism associated with morphine-associated reward memory and position GSDMD as a potential therapeutic target that warrants further investigation for mitigating opioid-induced maladaptive plasticity."

Journal • Preclinical • Addiction (Opioid and Alcohol) • CNS Disorders • Psychiatry • CA3 • IL1B

Lymphocyte count polygenicity underlies dimethyl fumarate-associated lymphopenia in multiple sclerosis. (PubMed, Mult Scler) - "Common polygenic variation of lymphocyte counts was significantly associated with moderate lymphopenia during DMF treatment."

Journal • CNS Disorders • Multiple Sclerosis